PDCD1 and asthma: In particular, therapeutic strategies that could ensure an optimal engagement of PD-1 on ILC2s would directly reduce asthma pathogenesis, notably IL-5-mediated eosinophil recruitment and IL-13-dependent mucus metaplasia in the respiratory tract.